FierceBiotechOriginal article
{"a":[{"_":"Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido","$":{"href":"/biotech/processa-acquires-vidya-potential-btk-inhibitor-rival-novartis-rhapsido","hreflang":"en"}}]}
RhapsidoVidya BTK inhibitorPositive
AI Analysis
Summary
Processa Pharmaceuticals has acquired Vidya Therapeutics to enter the autoimmune space with a BTK inhibitor candidate positioned as a potential rival to Novartis' Rhapsido.
Importance:6/10
Sentiment:
0.50
acquisitionautoimmuneBTK inhibitorcompetitive positioning
Read the original article
Published by FierceBiotech on July 29, 2026 10:12 AM
